The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche/Genentech
Honoraria - Amgen; PharmaMar; Roche/Genentech
Stefan Sleijfer
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Saskia Litière
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; PharmaMar; Roche/Genentech
Research Funding - GlaxoSmithKline; Novartis; PharmaMar; Roche
Axel Le Cesne
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Zsuzsanna Papai
No relevant relationships to disclose
Ian Robert Judson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Patrick Schoffski
No relevant relationships to disclose
Sant P. Chawla
No relevant relationships to disclose
Thierry Gil
No relevant relationships to disclose
Sophie Piperno-Neumann
No relevant relationships to disclose
Sandrine Marreaud
No relevant relationships to disclose
Rachel Hodge
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Winette T.A. Van Der Graaf
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline